Bruce Ames

Professor Bruce Ames, PhD

Co-chair, Scientific Advisory Board

Dr. Ames is a Professor of Biochemistry and Molecular Biology, University of California, Berkeley. Dr. Ames is well-known for his invention of the Ames Test, a biological assay to assess the mutagenic potential of chemical compounds. He currently serves on the Commission on Life Sciences for the National Academy of Sciences and was a member of the board of directors of the National Cancer Institute from 1976 to 1982. He was the recipient of the General Motors Cancer Research Foundation Prize (1983), the Tyler Environmental Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize awarded by the Japanese Emperor , (1997), the Kehoe Award, American College of Occupational And Environmental Medicine (1997), the Medal of the City of Paris (1998), the U.S. National Medal of Science awarded by President Clinton(1998), the Linus Pauling Institute Prize for Health Research (2001), and the American Society for Microbiology Lifetime Achievement Award (2001). He has contributed to over 450 publications and is one of the most-cited scientists in all fields.


Nai-Kong V. Cheung, MD, PhD

Member, Scientific Advisory Board

Dr. Cheung and Eureka have been closely working together on multiple collaboration projects since 2007. Dr. Cheung, Enid A. Haupt Endowed Chair in Pediatric Oncology at Memorial Sloan-Kettering Cancer Center, New York, NY, received his B.Sc. degree from the University of Chicago, as well as MD and PhD in Immunology from Harvard Medical School. He studied suppressor T cells and B cell tolerance under the mentorship of Dr. Baruj Benacerraf, the 1980 Nobel Laureate in Medicine. Upon completing pediatric training in Pediatrics and Pediatric Hematology/Oncology at Stanford University Medical Center, Dr. Cheung has devoted his career to translational science with a clinical focus on neuroblastoma, and a research focused on antibody-based therapies. His work has changed the outlook for children with high-risk metastatic neuroblastoma, including those with central nervous system metastases. His current research is directed at target discovery, antibody humanization and engineering, as well as novel platform technologies tailored for fast clinical translation for cancers in children and young adults.


Hideho Okada, MD, PhD

Member, Scientific Advisory Board

Dr. Okada, a pioneer in cancer immunotherapy, is a Kathleen M. Plant Distinguished Professor in Neurological Surgery and an investigator at the Parker Institute for Cancer Immunotherapy at University of California San Francisco (UCSF). He brings to the board over 20 years of extensive knowledge in the research and development of effective immunotherapies for brain tumors. His team conducted one of the first immunotherapy trials in patients with malignant glioma and was also one of the first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific antigens, pioneering the discoveries of novel immunoregulatory mechanisms in gliomas. He has translated these discoveries into a number of innovative immunotherapy clinical studies, in both adult and pediatric brain tumor patients.


David A. Scheinberg, MD, PhD

Member, Scientific Advisory Board

Dr. Scheinberg is currently Vincent Astor Chair and Chairman, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute; Chairman, Experimental Therapeutics Center, Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC.  As a physician-scientist, Dr. Scheinberg specializes in the care of patients with leukemia. He investigates new therapeutic approaches to cancer, both in the hospital and in the laboratory. The focus of his research is the discovery and development of novel, specific immunotherapeutic agents.  Eight different therapeutic agents developed by Dr. Scheinberg’s laboratory have reached human clinical trials, which include the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, the first tumor specific fusion oncogene product vaccines, and antibodies to intracellular proteins. Dr. Scheinberg has published more than 280 papers, chapters, or books in these fields.  Dr. Scheinberg received his bachelor’s degree from Cornell University and his M.D. degree and Ph.D. degree in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.


Professor Hsing-Jien Kung, PhD

Co-chair, Scientific Advisory Board

Dr. Kung is the current president of Taiwan National Health Research Institute. He was professor in Biological Chemistry at the University of California at Davis, School of Medicine. He is also the Director of Basic Science Research at the UC Davis Cancer Center. Dr. Kung is an internationally known scientist and cancer researcher. His current major research interests include signal transduction, oncogenes, tyrosine kinases, prostate cancer and cancer virology. Dr. Kung earned his Ph.D. from the California Institute of Technology in 1976, and his B.S. in Chemistry from the National Taiwan University in 1969.


Professor Peter Lee, MD

Member, Scientific Advisory Board

Dr. Lee is currently Chair of Cancer Immunotherapeutics & Tumor Immunology at City of Hope. His research focuses on understanding the biology of the immune response to cancer. Dr. Lee’s research seeks to establish how the immune system distinguishes between a normal cell and a cancer cell, the molecular mechanisms by which cancer cells modulate the immune response. Dr. Lee was the recipient of the Era of Hope Award for breast cancer research in 2006.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.